ALLIANCE PHARMACEUTICAL CORP
10-K, EX-27, 2000-09-01
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: ALLIANCE PHARMACEUTICAL CORP, 10-K, EX-23.1, 2000-09-01
Next: CLEAR CHANNEL COMMUNICATIONS INC, S-8 POS, 2000-09-01



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEETS AND THE CONSOLIDATED STATEMENTS OF OPERATIONS
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUN-30-2000
<PERIOD-START>                             JUL-01-1999
<PERIOD-END>                               JUN-30-2000
<CASH>                                      28,721,000
<SECURITIES>                                 4,806,000
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            34,995,000
<PP&E>                                      20,309,000
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              75,949,000
<CURRENT-LIABILITIES>                       23,670,000
<BONDS>                                              0
                                0
                                      5,000
<COMMON>                                       472,000
<OTHER-SE>                                  32,789,000
<TOTAL-LIABILITY-AND-EQUITY>                75,949,000
<SALES>                                              0
<TOTAL-REVENUES>                            16,000,000
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                          (64,365,000)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           1,961,000
<INCOME-PRETAX>                           (46,467,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                       (46,467,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (46,467,000)
<EPS-BASIC>                                     (1.03)
<EPS-DILUTED>                                   (1.03)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission